Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
HIV Eradication: One Step Closer
Scientists Crack Integrase Inhibitor Mystery
Gilead Reports Success With Quad Pill and Boosting Drug
New Hope for HIV Eradication
Study: Demand for HIV Vaccine Will Depend on How Good It Is
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

August 27, 2009

Tight Viral Control Is Key to Protecting Kidney Function

Strong control of HIV, whether naturally or through antiretroviral (ARV) therapy, significantly reduces the chance for decline in kidney function, according to a study published online August 25 in AIDS.

Some level of kidney disease can be found in up to 30 percent of HIV-infected people, and data clearly show a greater risk for kidney decline in people with HIV than their HIV-negative counterparts. Studies to discover the causes for this, however, have been mixed and sometimes contradictory. A handful of studies show that higher CD4 counts and lower viral load help protect kidneys. Many studies show that the loss of kidney function slows after starting HIV treatment, while other studies more clearly implicate that some or all ARVs are hard on the kidneys.

To identify the key risk factors for kidney decline, and to assess whether effective ARV therapy reduces the risk for kidney dysfunction, Andy Choi, MD, from the San Francisco Veterans Affairs Medical Center, and his colleagues examined the medical records of 615 HIV-positive participants from the Study of the Consequences Of the Protease inhibitor Era (SCOPE) cohort. Kidney function was measured by looking at the glomerular filtration rate (GFR).

Choi’s team broke the cohort down into three groups for analysis. One group included 82 people who recently started ARV therapy for the first time. A second group included people who kept viral loads below 500, but without the need for HIV treatment. A third group also maintained viral loads less than 500 copies, but were taking HIV treatment.

In the group that recently started ARV treatment, the team found that the participants on average were losing a minor to moderate degree of kidney function each year before starting treatment. After they started treatment, the decline in kidney function slowed considerably, but did not disappear.

In the two other groups of patients with low viral loads, the group controlling HIV naturally and not on ARV treatment had almost no loss of kidney function. The group on treatment, with low viral loads, had significantly more loss. However, in those not on treatment, with low viral loads, the risk of decline in kidney function did significantly increase in people who had short bursts of viral production, called “blips.”

The authors acknowledge that traditional risk factors for kidney disease, such as diabetes and race, still have a profound influence. In this study, people with the least control of HIV lost more kidney function than people with very tight viral control. The authors recommend paying careful attention to levels of virus in people on or off treatment with the aim of reducing kidney function loss.

Search: Kidney, viral load, Andy Choi, kidney disfuction


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16-19, 2010


5th IAS Conference on HIV Pathogenesis Treatment and Prevention (IAS 2009)
Cape Town, South Africa
July 19-22, 2009


16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Montréal, Canada
February 8-11, 2009

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy